Biogen Idec, Inc. (Massachusetts) Release: The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions Of ALPROLIX™ Effectively Controlled Bleeding In Hemophilia B Patients
Published: Dec 05, 2013
CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIXTM, the companies’ investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. The study appears in the Online First edition and will appear in the December 12 print issue of The New England Journal of Medicine (NEJM).
Help employers find you! Check out all the jobs and post your resume.